(177)Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial

What Was Tested

Researchers studied Octreotide and Somatostatin in this clinical trial, phase i publication.

The primary objective was to evaluate toxicity using National Cancer Institute Common Toxicity Criteria version 5.0.

Why It Was Studied

Secondary objectives included time to progression, overall survival, response rate, and dosimetry variables.

Five patients did not complete the 4 cycles because of progression, noncompliance, and carcinoid crisis after the first 177Lu-DOTATATE infusion.

Who Took Part

According to the abstract, 3 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Methods: Eighteen patients were enrolled, mostly with pancreatic or small intestinal neuroendocrine tumors or atypical lung carcinoids.

What Was Measured

Secondary objectives included time to progression, overall survival, response rate, and dosimetry variables.

Topics PubMed links to this paper include Phthalazines, Poly(ADP-ribose) Polymerase Inhibitors, Organometallic Compounds, Octreotide, Piperazines, Feasibility Studies and Neuroendocrine Tumors.

The authors tagged it with the keywords 177Lu-DOTATATE, PARP inhibitor, PRRT, peptide receptor radionuclide therapy and somatostatin receptors.

What This Means in Plain Language

This is a phase 1 clinical trial of Octreotide and Somatostatin in 3 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.